EP3197457 - 4'-VINYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS RNA REPLICATION [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 15.09.2023 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 07.10.2022 | ||
Former | Grant of patent is intended Status updated on 11.05.2022 | ||
Former | Examination is in progress Status updated on 24.07.2020 | ||
Former | Request for examination was made Status updated on 04.07.2017 | ||
Former | The international publication has been made Status updated on 26.04.2017 | Most recent event Tooltip | 07.06.2024 | Lapse of the patent in a contracting state New state(s): MC | published on 10.07.2024 [2024/28] | Applicant(s) | For all designated states Riboscience LLC 3901 Laguna Avenue Palo Alto, CA 94306 / US | [2017/31] | Inventor(s) | 01 /
SMITH, Mark 333 Harrison Street 363 San Francisco, California 94105 / US | 02 /
KLUMPP, Klaus G. 611 Winston Lane West Chester, Pennsylvania 19382 / US | [2017/31] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2017/31] | Application number, filing date | 15844391.1 | 25.09.2015 | [2017/31] | WO2015US52144 | Priority number, date | US201462055704P | 26.09.2014 Original published format: US 201462055704 P | [2017/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016049415 | Date: | 31.03.2016 | Language: | EN | [2016/13] | Type: | A1 Application with search report | No.: | EP3197457 | Date: | 02.08.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.03.2016 takes the place of the publication of the European patent application. | [2017/31] | Type: | B1 Patent specification | No.: | EP3197457 | Date: | 09.11.2022 | Language: | EN | [2022/45] | Search report(s) | International search report - published on: | US | 31.03.2016 | (Supplementary) European search report - dispatched on: | EP | 04.07.2018 | Classification | IPC: | C07H19/067, C07H19/10, C07H19/11, C07H19/167, C07H19/20, C07H19/213, A61K31/708, A61K31/7072, A61K31/7068, A61K31/7076, A61P31/14 | [2018/31] | CPC: |
C07H19/10 (EP,IL,KR,US);
C07H19/067 (EP,IL,KR,US);
A61P31/14 (EP,US);
C07H19/11 (EP,IL,US);
C07H19/167 (EP,IL,KR,US);
C07H19/20 (EP,IL,KR,US);
|
Former IPC [2017/31] | A61K31/52, A61K31/708 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/31] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | 4'-VINYLSUBSTITUIERTE NUKLEOSIDDERIVATE ALS HEMMER DER RNA-REPLIKATION DES RESPIRATORISCHEN SYNZYTIAL-VIRUS | [2017/31] | English: | 4'-VINYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS RNA REPLICATION | [2017/31] | French: | DÉRIVÉS DE NUCLÉOSIDE 4'-VINYLE SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DUE L'ARN DU VIRUS RESPIRATOIRE SYNCYTIAL | [2017/31] | Entry into regional phase | 26.04.2017 | National basic fee paid | 26.04.2017 | Search fee paid | 26.04.2017 | Designation fee(s) paid | 26.04.2017 | Examination fee paid | Examination procedure | 26.04.2017 | Examination requested [2017/31] | 26.04.2017 | Date on which the examining division has become responsible | 09.01.2018 | Despatch of communication of loss of particular rights: Claims {1} | 30.01.2019 | Amendment by applicant (claims and/or description) | 23.07.2020 | Despatch of a communication from the examining division (Time limit: M02) | 02.10.2020 | Reply to a communication from the examining division | 12.05.2022 | Communication of intention to grant the patent | 22.09.2022 | Fee for grant paid | 22.09.2022 | Fee for publishing/printing paid | 22.09.2022 | Receipt of the translation of the claim(s) | Opposition(s) | 10.08.2023 | No opposition filed within time limit [2023/42] | Request for further processing for: | Loss of rights: Claims | 13.02.2018 | Request for further processing filed | 13.02.2018 | Full payment received (date of receipt of payment) | Fees paid | Renewal fee | 22.09.2017 | Renewal fee patent year 03 | 26.09.2018 | Renewal fee patent year 04 | 13.09.2019 | Renewal fee patent year 05 | 14.09.2020 | Renewal fee patent year 06 | 15.09.2021 | Renewal fee patent year 07 | 11.08.2022 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 09.11.2022 | AT | 09.11.2022 | CZ | 09.11.2022 | DK | 09.11.2022 | EE | 09.11.2022 | ES | 09.11.2022 | FI | 09.11.2022 | HR | 09.11.2022 | LT | 09.11.2022 | LV | 09.11.2022 | MC | 09.11.2022 | NL | 09.11.2022 | PL | 09.11.2022 | RO | 09.11.2022 | RS | 09.11.2022 | SE | 09.11.2022 | SI | 09.11.2022 | SK | 09.11.2022 | SM | 09.11.2022 | NO | 09.02.2023 | GR | 10.02.2023 | IS | 09.03.2023 | PT | 09.03.2023 | [2024/28] |
Former [2023/51] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/38] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/37] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/35] | AT | 09.11.2022 | |
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/34] | AT | 09.11.2022 | |
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/33] | AT | 09.11.2022 | |
DK | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/29] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/26] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/24] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
PT | 09.03.2023 | ||
Former [2023/23] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
PT | 09.03.2023 | ||
Former [2023/22] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
LT | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
PT | 09.03.2023 | ||
Former [2023/20] | LT | 09.11.2022 | |
NO | 09.02.2023 | Documents cited: | Search | [IA]WO9816184 (ICN PHARMACEUTICALS [US], et al) [I] 1-5,16,18,19 * Claims, in particular claims 1, 8, 9 and 10; Page 11 lines 13-14; Examples * [A] 6-15,17,20; | [IA]WO0203997 (ICN PHARMACEUTICALS [US], et al) [I] 1-5,8,10,11,13,16-20 * Claims, in particular claims 1 and 10-21; page 14 lines 1-16; examples * [A] 6,7,9,12,14,15; | [XAI]US2004167096 (CHENG YUNG-CHI [US], et al) [X] 1-15,18,19 * Claims, in particular claims 1, 22, 26 and 27; 4'vinyl-thymidine in figure 1; paragraph [13] and Tables 1, 2a, 3a and 3b * [A] 16 [I] 17,20; | [A]WO2013096679 (ALIOS BIOPHARMA INC [US]) [A] 1-20 * Claims and examples *; | [XPA]WO2015054465 (ALIOS BIOPHARMA INC [US]) [XP] 1-16,19 * Claims and compound 303 in example 180 *[A] 17,18,20; | [E]WO2015200219 (ALIOS BIOPHARMA INC [US]) [E] 1-16,19 * Claims, in particular claims 1 and 99, and compound 303 in example 180 *; | [XA] - NOMURA M ET AL, "NUCLEOSIDES AND NUCLEOTIDES. 185. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF 4'ALPHA-C-BRANCHED-CHAIN SUGAR PYRIMIDINE NUCLEOSIDES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (19990101), vol. 42, no. 15, doi:10.1021/JM990050I, ISSN 0022-2623, pages 2901 - 2908, XP000915083 [X] 1,3-5,14,19 * Compound 19 in scheme 1 and page 2905 and HCl salt thereof * [A] 2,6-13,15-18,20 DOI: http://dx.doi.org/10.1021/jm990050i | [XA] - KODAMA E-I ET AL, "4'-ETHYNYL NUCLEOSIDE ANALOGS: POTENT INHIBITORS OF MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS VARIANTS IN VITRO", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20010501), vol. 45, no. 5, doi:10.1128/AAC.45.5.1539-1546.2001, ISSN 0066-4804, pages 1539 - 1546, XP001127402 [X] 1,3-5,19 * 4'-vinyl-thymidine in table * [A] 2,6-18,20 DOI: http://dx.doi.org/10.1128/AAC.45.5.1539-1546.2001 | [XA] - SMITH ET AL, "Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20070403), vol. 17, no. 9, doi:10.1016/J.BMCL.2007.02.004, ISSN 0960-894X, pages 2570 - 2576, XP022015347 [X] 1-5,14,15,19 * Compound 21 in scheme 3 and compound 32 in scheme 5 * [A] 6-13,16-18,20 DOI: http://dx.doi.org/10.1016/j.bmcl.2007.02.004 | [XA] - KIRCHHOFF C ET AL, "Dinucleotides of 4'-C-vinyl- and 5'-C-allylthymidine as substrates for ring-closing metathesis reactions", TETRAHEDRON LET, ELSEVIER, AMSTERDAM, NL, (20030818), vol. 44, no. 34, doi:10.1016/S0040-4039(03)01584-3, ISSN 0040-4039, pages 6475 - 6478, XP004442779 [X] 1,3-5 * Deprotected intermediate between (4) and (7) * [A] 2,6-20 DOI: http://dx.doi.org/10.1016/S0040-4039(03)01584-3 | International search | [XY]US2003236216 (DEVOS RENE ROBERT [GB], et al) [X] 1-2, 3/1-2 * ; paragraphs [0006]-[0011], [0014], [0020], [0023]-[0029], [0039] * [Y] 17, 20; | [A]US2004121980 (MARTIN JOSEPH ARMSTRONG [US], et al) [A] 1-2, 3/1-2, 17, 20* ; entire document *; | [Y]US2007042988 (KLUMPP KLAUS [US], et al) [Y] 17, 20 * ; paragraphs [0025]-[0026], [0029]-[0030], [0036]-[0037], [0077] *; | [A]US2013018011 (JAVANBAKHT HASSAN [US], et al) [A] 1-2, 3/1-2, 17, 20 * ; entire document * | by applicant | WO9816184 | WO0203997 | WO2013096679 | WO2015054465 | WO2015200219 | - LEE, N. et al., Clin Infect Dis, (20130000), vol. 57, no. 8, pages 1069 - 77 | - NAIR, H. et al., Lancet, (20100000), vol. 375, no. 9725, pages 1545 - 55 | - "Nucleoside Inhibitors of Hepatitis C Virus", KLUMPP, K. et al., Hepatitis C: Antiviral Drug Discovery and Development, Caister Academic Press, (20110000), pages 293 - 311 | - TIONG-YIP, C. L. et al., Antimicrob. Agents Chemother., (20140000), vol. 58, no. 7, pages 3867 - 3873 | - XIONG, H. et al., Bioorg. Med. Chem. Lett., (20130000), vol. 23, no. 24, pages 6789 - 6793 | - MASON, S. W., Nucleic Acids Res, (20040000), vol. 32, no. 16, pages 4758 - 4767 | - NOMURA M et al., J Med Chem, (19990000), vol. 42, no. 15, pages 2901 - 8 | - KODAMA EI et al., Antimicrob Agents Chemother, (20010000), vol. 45, no. 5, pages 1539 - 46 | - KIRCHHOFF C et al., Tetrahedron letters, (20030000), vol. 44, no. 34, pages 6475 - 8 | - FIESER, Fieser's Reagents for Organic Synthesis, Wiley & Sons, (19910000), vol. 1-40 | - RODD, Chemistry of Carbon Compounds, Elsevier Science Publishers, (19890000), vol. 1-5 | - J. Med. Chem., (20000000), vol. 43, page 4516 |